Psychiatric medications can change how psilocybin behaves in several distinct ways — by blunting 5-HT2A signaling, adding serotonergic load, lowering seizure threshold, stacking sedation or cardiovascular strain, or shifting the underlying psychiatric risk of the experience. The concern is not the same for every class. SSRIs, SNRIs, and antipsychotics are mostly associated with blunted or blocked effects; lithium is the one documented-danger signal, linked to seizures in case reports; MAOIs and serotonergic polypharmacy raise serious mechanistic concern. This page maps those concerns class by class. It is a safety map, not a compatibility chart: it describes what the evidence shows and where it stops, and nothing here should be used to start, stop, combine, or adjust a prescribed medication.
This is an evidence review, not medication guidance. Whether an interaction matters depends on dose, diagnosis, medication history, timing, and individual vulnerability. Nothing here should be used to start, stop, combine, or adjust a prescribed medication — those decisions belong with the clinician who prescribed it.
How to read this map
This page sits alongside the interactions overview and the per-class deep-dives, and pulls them into a single class-by-class reference. Two ideas hold the whole thing together.
First, interaction concerns are not all the same kind of concern. Some classes mainly blunt or block psilocybin’s effects; some add physiologic load (sedation, blood pressure, seizure threshold); some raise serotonergic load; and for many, the honest status is not characterized at all. Naming the type of concern is more useful than a single safe-or-unsafe verdict the evidence cannot support. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
Second, the published human evidence is genuinely thin. The first systematic review of psychiatric-medication interactions with psilocybin found only a small number of relevant human studies. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y A more recent scoping review of antidepressants taken with classic psychedelics found the combinations generally tolerated in the available studies, with no signal of increased serotonin syndrome — most clearly for psilocybin — while also flagging how limited and supervised that evidence is. [2] Systematic review Concomitant use of antidepressants and classic psychedelics: a scoping review doi:10.1177/02698811251368360 Both of those facts matter: the danger is usually unmeasured, and the reassurance is partial.
Dose context changes the stakes
Most of the public conversation is about microdosing, but medication-interaction concerns scale with exposure. The terms below are used consistently on this page.
| Term | What it refers to | Editorial caution |
|---|---|---|
| Microdosing | Sub-perceptual use, no acute psychedelic effect intended | Still not risk-free when psychiatric medications are involved |
| Macrodosing | Perceptual psychedelic dosing | Higher psychological, cardiovascular, and interaction uncertainty |
| High / immersive dosing | Strong perceptual or immersive doses | Highest-risk context; not presented here as a normal or recommended practice |
Interaction concerns generally become more consequential as the dose moves from sub-perceptual to perceptual to strong, because stronger receptor activation, larger psychological effects, and greater physiologic stress leave less room for an unexpected interaction. Lower dose lowers some risks; it does not erase the serious ones.
Antidepressants that act on serotonin: SSRIs and SNRIs
For the most common question — antidepressants — the better-supported finding is blunting, not acute danger. A retrospective survey reported weaker-than-expected psilocybin effects more often during SSRI and SNRI use than with bupropion, with dampening that persisted for some people for months after discontinuation. [3] Observational Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use doi:10.1177/02698811231179910 Importantly, blunting is not the same as safety: a person who misreads a muted response as “nothing happened” may escalate exposure, which is its own hazard, and one that grows in macrodosing and high-dose contexts. A controlled trial complicates the simple blunting story — two-week escitalopram pretreatment did not flatten psilocybin’s positive mood effects, mainly its adverse ones. [4] Clinical trial Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects doi:10.1002/cpt.2487 The fuller treatment is in SSRIs, SNRIs and microdosing.
| Generic | Common brand(s) | Class | Primary interaction concern with psilocybin |
|---|---|---|---|
| Sertraline | Zoloft | SSRI | Possible blunting; serotonergic overlap; do not stop abruptly |
| Escitalopram / citalopram | Lexapro / Celexa | SSRI | Possible blunting; controlled data show positive effects may persist |
| Fluoxetine | Prozac | SSRI | Possible blunting; long half-life extends the interaction window after stopping |
| Paroxetine | Paxil | SSRI | Possible blunting; notable discontinuation effects if stopped abruptly |
| Venlafaxine / desvenlafaxine | Effexor / Pristiq | SNRI | Possible blunting; added noradrenergic/autonomic and blood-pressure considerations |
| Duloxetine | Cymbalta | SNRI | Possible blunting; serotonergic/noradrenergic overlap |
The class as a whole is defined by serotonergic reuptake inhibition; the FDA’s drug-class information is a neutral reference for the agents involved. [5] Government Selective Serotonin Reuptake Inhibitors (SSRIs) Information Link → Decisions about tapering or stopping any antidepressant sit entirely with a prescriber.
Other serotonergic and atypical antidepressants
Several antidepressants are not classic SSRIs but still touch serotonin or carry their own concerns. Serotonin modulators (such as vortioxetine), serotonin-antagonist/reuptake inhibitors (trazodone, nefazodone), and 5-HT1A-acting agents (buspirone) raise questions of blunting, sedation, or more complex serotonergic overlap rather than a single clean prediction. Bupropion is relevant for a different reason: it is less associated with serotonergic blunting, but it can lower seizure threshold, which is a more pointed concern in high-dose contexts. Mirtazapine adds sedation and mixed receptor effects; ketamine and esketamine raise dissociation, blood-pressure, and perceptual concerns that make any combination unpredictable. The absence of psilocybin-specific data for these agents is not evidence of safety.
Tricyclic antidepressants
Tricyclics act on serotonin and norepinephrine but also on histamine, acetylcholine, and cardiac conduction. With psilocybin the concern is therefore broader than serotonin overlap: anticholinergic burden, sedation, confusion, blood-pressure effects, and cardiac unpredictability, all of which become more consequential at perceptual and high doses. Representative agents include amitriptyline (Elavil), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), and doxepin (Sinequan, Silenor).
MAOIs and MAOI-like agents
MAOIs are a high-caution category for a mechanistic reason that combines two routes at once: they slow the breakdown of monoamines — psilocin is partly cleared by monoamine oxidase, so exposure can rise and prolong — and they raise systemic serotonin, increasing total serotonergic load. [6] Peer-reviewed Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance doi:10.1080/03602532.2016.1278228 [7] Peer-reviewed The serotonin syndrome doi:10.1056/NEJMra041867 Psilocybin is not MDMA and should not be treated as a serotonin-releasing drug, but combining a serotonergic psychedelic with MAOI physiology introduces enough uncertainty that the category belongs outside ordinary self-directed use. The class is also not uniform: irreversible MAOIs (phenelzine/Nardil, tranylcypromine/Parnate), MAO-B–selective agents (selegiline, rasagiline), and non-psychiatric MAO inhibitors (linezolid, methylene blue) differ in potency, reversibility, and duration. Detail is in MAOIs and microdosing.
Mood stabilizers — and the lithium signal
Lithium is the firmest danger signal in this entire cluster. An analysis of online experience reports found seizures in a striking share of lithium-plus-classic-psychedelic accounts, while none appeared in the lamotrigine comparison. [8] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794 This does not establish a mechanism or an incidence rate, but a seizure is a serious enough outcome that lithium is treated as a red-flag interaction across dose levels — the full discussion is in lithium and psilocybin. Other stabilizers (valproate, carbamazepine, oxcarbazepine, topiramate, gabapentin, pregabalin) raise CNS-effect and interpretation concerns rather than the lithium-specific seizure signal, and lamotrigine did not show that signal in the available reports.
Antipsychotics
Antipsychotics are the cleanest mechanistic case: many block or modulate the 5-HT2A receptor that psilocin acts through, so the expected result is reduced or abolished effect rather than amplification. [9] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 But two cautions sit on top of that. First, “it probably won’t work” is not “it is safe.” Second, and more important, antipsychotics are prescribed for conditions — psychosis, mania, severe mood instability — that psychedelic research routinely excludes for safety reasons, so the indication itself can carry risk that receptor pharmacology does not capture. This is treated in antipsychotics and microdosing.
Benzodiazepines, Z-drugs, and sedatives
Sedative-hypnotics — benzodiazepines (alprazolam, clonazepam, diazepam, lorazepam), Z-drugs (zolpidem, eszopiclone), and related agents — may dull anxiety or reduce intensity, but they introduce their own load: sedation, memory disruption, confusion, impaired coordination, and poorer decision-making. In supervised clinical settings a benzodiazepine may be used to manage acute agitation, but that is not a template for self-directed combination. The concern here is additive impairment rather than a specific serotonergic interaction.
Stimulants and ADHD medications
Stimulants (mixed amphetamine salts/Adderall, lisdexamfetamine/Vyvanse, methylphenidate/Ritalin) and noradrenergic ADHD agents (atomoxetine, guanfacine, clonidine) act largely on different systems than psilocin, so the main concern is not a shared receptor target but additive activation: arousal, heart rate, blood pressure, anxiety, appetite suppression, and disrupted sleep stacking in ways that are hard to interpret. In macrodosing and high-dose contexts that can mean more panic, agitation, or cardiovascular discomfort. The focus question is especially hard to read, because the medication already targets attention — covered in stimulants and ADHD medications.
A rough risk-language hierarchy
The classes above do not deserve identical language. The grouping below is a way to keep proportion — it is descriptive, not a set of instructions.
| Posture | Where it applies |
|---|---|
| Red-flag / outside self-directed use | Lithium; MAOIs; antipsychotic use for psychosis or mania; high-dose contexts with major psychiatric medication |
| High caution | SSRIs/SNRIs at perceptual or high doses; tricyclics; stimulants; ketamine/esketamine; sedatives |
| Blunting likely or possible | SSRIs, SNRIs, antipsychotics, some sedatives |
| Limited or uncertain data | Buspirone, mirtazapine, gabapentin/pregabalin, lamotrigine |
- Map, not a compatibility chart
- This page describes the kind of interaction concern each class raises; it is not a list of safe combinations and does not endorse any. [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y
- Blunting ≠ safety
- SSRIs, SNRIs, and antipsychotics mostly reduce or block effects; a muted response can tempt unsafe escalation, which is its own hazard. [3] Observational Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use doi:10.1177/02698811231179910
- Lithium is the red flag
- Lithium plus a classic psychedelic is the cluster’s one documented-danger signal, on the basis of seizure reports. [8] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794
- Reassurance is partial
- The most favorable recent review found antidepressant co-use generally tolerated with no serotonin-syndrome signal, but on a small, supervised evidence base. [2] Systematic review Concomitant use of antidepressants and classic psychedelics: a scoping review doi:10.1177/02698811251368360
- Dose raises the stakes
- Interaction concerns generally grow from microdose to macrodose to high dose; lower dose lowers some risks but not the serious ones.
Frequently asked questions
Should I stop or change my medication before microdosing?
No. Stopping, switching, or adjusting a prescribed medication carries its own serious risks — withdrawal, relapse, mood destabilization, or symptom rebound — independent of anything to do with psilocybin. Those decisions belong with the prescribing clinician who knows your history. This library describes what the research does and does not show; it is not a basis for changing treatment, and nothing here should be read as a reason to alter a prescribed medication on your own.
Does this page tell me which medications are safe to combine with psilocybin?
No. This is a map of interaction concerns, not a compatibility chart. For most medication classes there is little or no direct human evidence about combination with psilocybin, [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y and even where there is, “tolerated in a supervised study” is not the same as “safe in self-directed use”. [2] Systematic review Concomitant use of antidepressants and classic psychedelics: a scoping review doi:10.1177/02698811251368360 The page describes the kind of concern each class raises — blunting, additive load, seizure-threshold, serotonergic load — and where that concern is grounded in evidence versus pharmacology. Any decision about combining a psychoactive substance with a prescribed medication belongs with a clinician.
Do these interaction concerns get worse at higher doses?
Generally yes, though not uniformly. Concerns tend to become more consequential as the dose moves from sub-perceptual to perceptual to strong, because stronger receptor activation, larger psychological effects, and greater physiologic stress leave less room for an unexpected interaction. But lower dose does not automatically erase risk: some concerns, such as the lithium seizure signal, are serious enough that the lack of low-dose data is itself a reason for caution. [8] Observational Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports doi:10.1055/a-1524-2794
Is the absence of reports about my medication a sign that it's fine?
No. A lack of published reports does not prove safety; it often means the combination has not been studied, reported, or recognized. Many classes here have little or no psilocybin-specific evidence, [1] Systematic review Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review doi:10.1007/s00213-022-06083-y so “no known interaction” should be read as “not characterized”, not “shown to be low-risk”.